Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01078376 · ClinicalTrials.gov registry record · Phase 1
A Comparative Single-Dose Pharmacokinetic (PK) and Safety Study of Azilsartan Medoxomil in Children With Hypertension and in Healthy Adults
A Phase 1 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT01078376 is a Phase 1 study that was terminated before completion, run by Takeda. The registered enrollment target is 29 participants.
The verdict
NCT01078376, a Phase 1 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this study was to assess the pharmacokinetics (PK) and safety of a single dose of azilsartan medoxomil in children with hypertension, and comparative PK in healthy adults.
Interventions
- DRUG Azilsartan medoxomil (TAK-491)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2010-05 |
| Est. Completion | 2013-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01078376
The ClinicalTrials.gov registry entry for NCT01078376 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Azilsartan medoxomil (TAK-491) is the first listed.
NCT01078376 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01078376 about?
NCT01078376 is a clinical study titled "A Comparative Single-Dose Pharmacokinetic (PK) and Safety Study of Azilsartan Medoxomil in Children With Hypertension and in Healthy Adults". The purpose of this study was to assess the pharmacokinetics (PK) and safety of a single dose of azilsartan medoxomil in children with hypertension, and comparative PK in healthy adults.
What is the current status of trial NCT01078376?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2010-05. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01078376?
The interventions under investigation include: Azilsartan medoxomil (TAK-491) (DRUG).
Who is sponsoring clinical trial NCT01078376?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.